Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)
In a report released on May 8, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $38.00. The company's shares closed yesterday at $3.08.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Wang is a 3-star analyst with an average return of 2.3% and a 39.26% success rate. Wang covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Legend Biotech.
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.14, implying a 975.97% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.
Based on 4D Molecular Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1 thousand and a GAAP net loss of $49.67 million. In comparison, last year the company had a GAAP net loss of $32.28 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
12 minutes ago
- Business Insider
Stifel Nicolaus Remains a Sell on Alpha and Omega (AOSL)
In a report released on June 6, Tore Svanberg from Stifel Nicolaus maintained a Sell rating on Alpha and Omega (AOSL – Research Report), with a price target of $18.00. The company's shares closed last Friday at $22.97. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Svanberg is a 5-star analyst with an average return of 15.2% and a 58.67% success rate. Svanberg covers the Technology sector, focusing on stocks such as Semtech, Credo Technology Group Holding Ltd, and Marvell. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alpha and Omega with a $26.67 average price target. Based on Alpha and Omega's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $164.64 million and a GAAP net loss of $10.81 million. In comparison, last year the company earned a revenue of $150.06 million and had a GAAP net loss of $11.21 million
Business Insider
25 minutes ago
- Business Insider
Jefferies software analyst holds an analyst/industry conference call
Software Analyst Samana, along with Sam Melehy, Practice Lead at Enterprise Vision Technologies and SerivceNOW Partner, discuss the current enterprise demand environment, as well as pipeline activity for the rest of 2025 on an Analyst/Industry conference call to be held on June 9 at 2 pm. Webcast Link Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
4 hours ago
- Business Insider
Geely chairman says auto industry facing ‘serious overcapacity', Reuters says
Geely's chairman and founder Li Shufu said the global automotive industry is facing 'serious overcapacity' and the company has decided to not build new manufacturing plants or expand production at its current facilities, Reuters reports. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
